Norway's Vistin Pharma Q3 profit falls

Overview

• Norway pharmaceutical firm's Q3 revenue was flat yr/yr as currency strength offset volume growth

• Q3 EBITDA and net profit declined compared to last year

• Company declared additional NOK 0.50/share cash dividend for Q4

Outlook

• Company continues to focus on sales volume growth and onboarding new customer volume in 2026

• Company to pay additional NOK 0.50 per share cash dividend in Q4 2026

Result Drivers

• VOLUME GROWTH OFFSET BY CURRENCY - Co said higher sales volumes were offset by a stronger NOK against EUR, impacting revenue in local currency

• NEW CUSTOMER VOLUME - Co said onboarding new customer volume helped increase sales volume and utilize manufacturing capacity

Company press release:

Key Details

Reuters Recommended Reads

• Oct 27 - Pharming Group Q3 revenue rises on US demand; tightens guidance

• Oct 28 - GSK pipeline doubts, vaccine underperformance overshadow sales beat

• Oct 28 - Generic drugmaker Sandoz cuts sales outlook, shares fall

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)